About Wanjia CSI Hong Kong Connect Innovative Drug Exchange Traded Fund Units

520700 invests in stocks. The fund's major sectors are Health Technology, with 92.34% stocks, and Commercial Services, with 1.33% of the basket. The assets are mostly located in the Asia region.

520700 top holdings are Innovent Biologics, Inc. and Wuxi Biologics (Cayman) Inc., occupying 9.58% and 9.51% of the portfolio correspondingly.

520700 assets under management is ‪952.38 M‬ CNY. It's risen 11.09% over the last month.

520700 fund flows account for ‪531.34 M‬ CNY (1 year). Many traders use this metric to get insight into investors' sentiment and evaluate whether it's time to buy or sell the fund.

520700 shares are issued by Wanjia Fund Management Co Ltd. under the brand Wanjia. The ETF was launched on Sep 13, 2024, and its management style is Passive.

520700 follows the CSI Hong Kong Stock Connect Innovative Drug Index - CNY - Benchmark TR Net. ETFs usually track some benchmark seeking to replicate its performance and guide asset selection and objectives.

520700 invests in stocks.

520700 price has risen by 7.95% over the last month, and its yearly performance shows a 97.51% increase. See more dynamics on 520700 price chart.
NAV returns, another gauge of an ETF dynamics, have risen by 1.61% over the last month, showed a 32.06% increase in three-month performance and has increased by 108.21% in a year.